prof. dr. Fritz Offner
- Work address
-
C. Heymanslaan 10, ingang 12 - verdieping 6
9000 Gent - Fritz.Offner@UGent.be
- ORCID iD
-
0000-0003-4690-3603
Show
Sort by
-
- Journal Article
- open access
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma
-
- Journal Article
- open access
Covalent Cysteine Targeting of Bruton's Tyrosine Kinase (BTK) Family by Withaferin-A Reduces Survival of Glucocorticoid-Resistant Multiple Myeloma MM1 Cells
-
- Journal Article
- A1
- open access
Circulating RNA biomarkers in diffuse large B-cell lymphoma : a systematic review
-
Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential
-
Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study
-
Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma
-
Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study
-
Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial
-
Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial
-
- Conference Paper
- open access
HEALTH UTILITY IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (RR-DLBCL) PATIENTS - RESULTS OF A PHASE II TRIAL WITH ORAL SELINEXOR